X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 44c
May 6, 2021 8:25 AM EDTX4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of ($1.30), $0.44 worse than the analyst estimate of ($0.86).
We are excited by the strong progress we have achieved to date in 2021 in the development of mavorixafor across multiple rare disease indications, said Paula Ragan, Ph.D., President and Chief... More
